Last: | $17.50 |
---|---|
Change Percent: | -0.35% |
Open: | $17.42 |
Close: | $17.50 |
High: | $17.5 |
Low: | $17.214 |
Volume: | 18,512 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$17.5 | $17.42 | $17.5 | $17.5 | $17.214 | 18,512 | 07-22-2024 |
$17.36 | $17.57 | $17.36 | $17.57 | $17.3 | 10,315 | 07-19-2024 |
$17.59 | $17.9 | $17.59 | $17.97 | $17.59 | 14,811 | 07-18-2024 |
$17.81 | $17.84 | $17.81 | $17.87 | $17.7 | 2,489 | 07-17-2024 |
$17.72 | $17.49 | $17.72 | $17.89 | $17.4401 | 36,380 | 07-16-2024 |
$17.6 | $17.875 | $17.6 | $17.875 | $17.47 | 18,373 | 07-15-2024 |
$17.45 | $17.2 | $17.45 | $17.5942 | $17.18 | 8,965 | 07-12-2024 |
$17.28 | $17.4 | $17.28 | $17.56 | $17.1 | 12,217 | 07-11-2024 |
$17.28 | $17.07 | $17.28 | $17.37 | $17.07 | 6,242 | 07-10-2024 |
$17.07 | $17.37 | $17.07 | $17.95 | $16.95 | 20,525 | 07-09-2024 |
$17.51 | $17.7734 | $17.51 | $17.7734 | $17.34 | 11,079 | 07-08-2024 |
$17.73 | $17.54 | $17.73 | $17.9378 | $17.54 | 17,695 | 07-05-2024 |
$17.68 | $17.54 | $17.68 | $17.7457 | $17.3633 | 9,710 | 07-04-2024 |
$17.68 | $17.54 | $17.68 | $17.7457 | $17.3633 | 9,710 | 07-03-2024 |
$17.54 | $17.43 | $17.54 | $17.62 | $17.22 | 12,153 | 07-02-2024 |
$17.44 | $17.39 | $17.44 | $17.57 | $17.14 | 13,660 | 07-01-2024 |
$17.23 | $17.58 | $17.23 | $17.58 | $17.06 | 14,985 | 06-28-2024 |
$17.49 | $17.75 | $17.49 | $17.75 | $17.38 | 6,919 | 06-27-2024 |
$17.63 | $17.23 | $17.63 | $17.65 | $17.1 | 22,129 | 06-26-2024 |
$17.11 | $17.37 | $17.11 | $17.61 | $17.06 | 9,569 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...
2024-07-13 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....